MARKET

CYTK

CYTK

Cytokinetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.03
+0.02
+0.17%
After Hours: 12.03 0 0.00% 16:08 01/27 EST
OPEN
11.95
PREV CLOSE
12.01
HIGH
12.15
LOW
11.62
VOLUME
750.44K
TURNOVER
--
52 WEEK HIGH
14.94
52 WEEK LOW
5.75
MARKET CAP
710.76M
P/E (TTM)
-5.7809
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CYTK and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CYTK News

  • Cytokinetics Announces Recipients of Second Annual Communications Fellowship Grants
  • GlobeNewswire.5d ago
  • Implied Volatility Surging for Cytokinetics (CYTK) Stock Options
  • Zacks.01/17 14:26
  • Cytokinetics Announces Vision 2025 and Outlines 2020 Corporate Milestones
  • GlobeNewswire.01/13 12:30
  • Wall Street Views on American Water Works, Royal Caribbean and Others
  • Barrons.com.01/11 01:10

More

Industry

Biotechnology & Medical Research
-0.88%
Pharmaceuticals & Medical Research
-0.51%

Hot Stocks

Name
Price
%Change

About CYTK

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.
More

Webull offers Cytokinetics, Inc. (CYTK) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.